2006 Concentrates Epilepsy Patients 
Project CBD
MARCH 21, 2023
Whatever the precise nature of the phantom sound, it often comes with a constellation of symptoms related to the disruption such a condition can bring: sleep problems, difficulty concentrating, low mood, etc. But many more patients were willing to try, perhaps as an indication of the intractability of chronic tinnitus.
Healer
DECEMBER 17, 2021
Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Patients using warfarin need to have their blood INR level tested after adding THC-containing cannabis to their regimen. topiramate. rufinamide. zonisamide. eslicarbazepine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 12, 2019
Side effects were very prevalent in 79% of all patients taking a refined CBD product, some of which were severe like thrombocytopenia and transaminase elevations in the liver. Review: During an open-label trial of pure CBD with Lennox-Gastaut and Dravet patients, 79% of all patients reported side effects.
Healer
DECEMBER 17, 2021
Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions.[1]. Patients using warfarin need to have their blood INR level tested after adding THC-containing cannabis to their regimen. topiramate. rufinamide. zonisamide. eslicarbazepine.
Cannabis Law Report
NOVEMBER 24, 2021
However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Patients can legally access medicinal cannabis through a doctor, via the TGA’s Authorised Prescribers and Special Access schemes.
Cannabis Law Report
SEPTEMBER 23, 2019
Marijuana and related substance misuse are complex issues impacting family medicine, patient health, and public health. Barriers to facilitating both clinical and public health research regarding marijuana is detrimental to treating patients and the health of the public. Executive Summary. Relevant AAFP Policy. Call to Action.
Cannabis Law Report
FEBRUARY 1, 2020
While much of this development has been concentrated in Europe and the US, several nations in Asia-Pacific have also recently shifted towards greater tolerance. There are now over 1,000 registered patients receiving medical marijuana products by prescription, and this number is projected to surge to 400,000 by 2028. NEW ZEALAND.
Expert insights. Personalized for you.
144 
Let's personalize your content